Shock is a life-threatening condition that requires prompt recognition and treatment to prevent organ failure. In the intensive care unit, shock is a common presentation, and its management is challenging. Critical care ultrasound has emerged as a reliable and reproducible tool in diagnosing and classifying shock. This comprehensive review proposes an ultrasound-based protocol for the hemodynamic assessment of shock to guide its management in the ICU. The protocol classifies shock as either low or high cardiac index and differentiates obstructive, hypovolemic, cardiogenic, and distributive etiologies. In distributive shock, the protocol proposes a hemodynamic-based approach that considers the presence of dynamic obstruction, fluid responsiveness, fluid tolerance, and ventriculo-arterial coupling. The protocol gives value to quantitative measures based on critical care ultrasound to guide hemodynamic management. Using critical care ultrasound for a comprehensive hemodynamic assessment can help clinicians diagnose the etiology of shock and define the appropriate treatment while monitoring the response. The protocol’s use in the ICU can facilitate prompt recognition, diagnosis, and management of shock, ultimately improving patient outcomes.
Background/Objectives: Anemia is common in critically ill patients, yet red blood cell (RBC) transfusion without active bleeding does not consistently improve outcomes and carries risks such as pulmonary injury, fluid overload, and increased costs. Optimal transfusion thresholds remain debated, with some guidelines recommending a restrictive target of 7 g/dL instead of a more liberal target of 9 g/dL. Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines, searching PubMed, EMBASE, and LILACS from January 1995 to October 2024. Thirteen randomized controlled trials involving 13,705 critically ill adults were included, with 6855 assigned to liberal and 6850 to restrictive transfusion strategies. The risk of bias was assessed using the Cochrane Risk of Bias Tool 2, and the pooled effect sizes were estimated with a random-effects model. We registered the protocol in PROSPERO International Prospective Register of Systematic Reviews (CDR42024589225). Results: No statistically significant difference was observed in 30-day mortality between restrictive and liberal strategies (odds ratio [OR] 1.02; 95% confidence interval [CI], 0.83–1.25; I2 = 49%). Similarly, no significant differences emerged for the 90-day or 180-day mortality, hospital or intensive care unit (ICU) length of stay, dialysis requirement, or incidence of acute respiratory distress syndrome (ARDS). However, patients in the restrictive group received significantly fewer RBC units. The trial sequential analysis (TSA) indicated that the evidence accrued was insufficient to definitively confirm or exclude an effect on the 30-day mortality, as the required sample size was not reached. Conclusions: In conclusion, while our meta-analysis found no statistically significant difference in the short-term mortality between restrictive and liberal transfusion strategies, larger trials are needed to fully determine whether any clinically meaningful difference exists in critically ill populations.
Background: Difficult weaning from mechanical ventilation remains a major challenge in intensive care units (ICUs), particularly among patients requiring prolonged respiratory support. High-flow tracheal therapy (HFTT) may improve gas exchange, humidification, and comfort in tracheostomized patients, but its clinical impact on weaning duration is uncertain. Methods: We conducted a retrospective cohort study including critically ill adult patients who underwent tracheostomy between 2020 and 2023. Patients received either HFTT or conventional oxygen therapy via tracheostomy mask. The primary outcome was post-tracheostomy mechanical ventilation duration, defined as the number of days from tracheostomy to successful ventilatory support withdrawal. Propensity score matching was performed using age, sex, Sequential Organ Failure Assessment (SOFA) score, presence of acute respiratory distress syndrome (ARDS), and sedation duration. Between-group comparisons employed parametric or nonparametric tests as appropriate, and a negative binomial regression model assessed potential associations with weaning duration. Results: Of 207 screened patients, 65 were included after matching (HFTT group = 19, tracheostomy mask group = 46). Baseline characteristics were balanced. The median post-tracheostomy weaning duration was 13 [8–19] days in the HFTT group and 11 [6–17] days in the tracheostomy mask group ( p = 0.47). Total mechanical ventilation time was longer in the HFTT group ( p = 0.02), but HFTT use was not associated with the post-tracheostomy weaning duration (β = 0.01 ± 0.22, p = 0.96). Conclusions: In this matched cohort, high-flow tracheal therapy did not shorten the weaning duration after tracheostomy compared with conventional oxygen therapy. Prospective studies are needed to clarify its optimal clinical role.